Literature DB >> 22614899

Stavudine concentrations in women receiving postpartum antiretroviral treatment and their breastfeeding infants.

Jessica M Fogel1, Taha E Taha, Jin Sun, Donald R Hoover, Teresa L Parsons, Johnstone J Kumwenda, Lynne M Mofenson, Mary Glenn Fowler, Craig W Hendrix, Newton I Kumwenda, Susan H Eshleman, Mark Mirochnick.   

Abstract

First-line antiretroviral treatment regimens in resource-limited settings used in breastfeeding mothers often include stavudine (d4T). Limited data describing d4T concentrations in breast milk are available. We analyzed d4T concentrations in 52 mother-infant pairs using ultra-performance liquid chromatography-tandem mass spectrometry (lower limit of quantification: 5 ng/mL in plasma, 20 ng/mL in breast milk). Median (interquartile range) d4T concentrations were 86 (36-191) ng/mL in maternal plasma, 151 (48-259) ng/mL in whole milk, 190 (58-296) ng/mL in skim milk, and <5 (<5 to <5) ng/mL in infant plasma. Although d4T is concentrated in breast milk relative to maternal plasma, the infant d4T dose received from breast milk is very small and not clinically significant.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22614899      PMCID: PMC3404155          DOI: 10.1097/QAI.0b013e31825ddcfa

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  13 in total

1.  Antiretroviral concentrations in breast-feeding infants of women in Botswana receiving antiretroviral treatment.

Authors:  Roger L Shapiro; Diane T Holland; Edmund Capparelli; Shahin Lockman; Ibou Thior; Carolyn Wester; Lisa Stevens; Trevor Peter; Max Essex; James D Connor; Mark Mirochnick
Journal:  J Infect Dis       Date:  2005-07-27       Impact factor: 5.226

2.  Nelfinavir and its active metabolite, hydroxy-t-butylamidenelfinavir (M8), are transferred in small quantities to breast milk and do not reach biologically significant concentrations in breast-feeding infants whose mothers are taking nelfinavir.

Authors:  Paul J Weidle; Clement Zeh; Amy Martin; Richard Lando; Frank Angira; Joseph Osoga; Paul Ogindo; Sonali Girde; Timothy D Minniear; Timothy K Thomas
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

3.  Determination of dosing guidelines for stavudine (2',3'-didehydro-3'-deoxythymidine) in children with human immunodeficiency virus infection.

Authors:  S Kaul; M W Kline; J A Church; L M Dunkle
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

4.  Pharmacokinetics and safety of stavudine in HIV-infected pregnant women and their infants: Pediatric AIDS Clinical Trials Group protocol 332.

Authors:  Nancy A Wade; Jashvant D Unadkat; Sharon Huang; David E Shapiro; Anita Mathias; Salih Yasin; Gregory Ciupak; D Heather Watts; Isaac Delke; Mobeen Rathore; Jane Hitti; Lisa Frenkel; Renee Samelson; Mary Elizabeth Smith; Lynne Mofenson; Sandra K Burchett
Journal:  J Infect Dis       Date:  2004-11-10       Impact factor: 5.226

5.  The effect of highly active antiretroviral treatment on viral load and antiretroviral drug levels in breast milk.

Authors:  Robert Colebunders; Beata Hodossy; David Burger; Tania Daems; Kristien Roelens; Marc Coppens; Ben Van Bulck; Yves Jacquemyn; Eric Van Wijngaerden; Katrien Fransen
Journal:  AIDS       Date:  2005-11-04       Impact factor: 4.177

6.  Postnatal HIV-1 transmission after cessation of infant extended antiretroviral prophylaxis and effect of maternal highly active antiretroviral therapy.

Authors:  Taha E Taha; Johnstone Kumwenda; Stephen R Cole; Donald R Hoover; George Kafulafula; Mary Glenn Fowler; Michael C Thigpen; Qing Li; Newton I Kumwenda; Lynne Mofenson
Journal:  J Infect Dis       Date:  2009-11-15       Impact factor: 5.226

7.  Extended antiretroviral prophylaxis to reduce breast-milk HIV-1 transmission.

Authors:  Newton I Kumwenda; Donald R Hoover; Lynne M Mofenson; Michael C Thigpen; George Kafulafula; Qing Li; Linda Mipando; Kondwani Nkanaunena; Tsedal Mebrahtu; Marc Bulterys; Mary Glenn Fowler; Taha E Taha
Journal:  N Engl J Med       Date:  2008-06-04       Impact factor: 91.245

Review 8.  Antiretroviral activity of stavudine (2',3'-didehydro-3'-deoxythymidine, D4T).

Authors:  S A Riddler; R E Anderson; J W Mellors
Journal:  Antiviral Res       Date:  1995-06       Impact factor: 5.970

9.  Antiretroviral concentrations in breast-feeding infants of mothers receiving highly active antiretroviral therapy.

Authors:  Mark Mirochnick; Timothy Thomas; Edmund Capparelli; Clement Zeh; Diane Holland; Rose Masaba; Prisca Odhiambo; Mary Glenn Fowler; Paul J Weidle; Michael C Thigpen
Journal:  Antimicrob Agents Chemother       Date:  2008-12-29       Impact factor: 5.191

10.  Studies on antiretroviral drug concentrations in breast milk: validation of a liquid chromatography-tandem mass spectrometric method for the determination of 7 anti-human immunodeficiency virus medications.

Authors:  Naser L Rezk; Nicole White; Arlene S Bridges; Mohamed F Abdel-Megeed; Tarek M Mohamed; Said S Moselhy; Angela D M Kashuba
Journal:  Ther Drug Monit       Date:  2008-10       Impact factor: 3.681

View more
  3 in total

Review 1.  Is infant exposure to antiretroviral drugs during breastfeeding quantitatively important? A systematic review and meta-analysis of pharmacokinetic studies.

Authors:  Catriona John Waitt; Paul Garner; Laura Jayne Bonnett; Saye Hock Khoo; Laura Jayne Else
Journal:  J Antimicrob Chemother       Date:  2015-04-08       Impact factor: 5.790

2.  Association of pol diversity with antiretroviral treatment outcomes among HIV-infected African children.

Authors:  Iris Chen; Leila Khaki; Jane C Lindsey; Carrie Fry; Matthew M Cousins; Robert F Siliciano; Avy Violari; Paul Palumbo; Susan H Eshleman
Journal:  PLoS One       Date:  2013-11-27       Impact factor: 3.240

3.  Estimation of Drug Pharmacokinetics from Breast Feeding: A Simple Method Based on Meta-analysis.

Authors:  Oumar Aboubacar Alassane; De Pablos-Martinez Carlos; Maiga Mamoudou; Dao Sounkalo; Chatelut Etienne; Gandia Peggy
Journal:  J Adv Med Pharm Sci       Date:  2019-08-03
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.